

Taru Annika Muranen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5217385/publications.pdf>

Version: 2024-02-01

61
papers

5,765
citations

117625

34
h-index

128289

60
g-index

64
all docs

64
docs citations

64
times ranked

9356
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960
2	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	21.4	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
4	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
5	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
7	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
8	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
9	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	1.6	162
10	Age- and Tumor Subtype-specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	1.6	152
11	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
12	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
13	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. <i>Cancer Research</i> , 2016, 76, 5103-5114.	0.9	100
14	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	6.3	99
15	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	6.2	98
16	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	5.0	97
17	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
18	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	5.0	78

#	ARTICLE	IF	CITATIONS
19	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76
20	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. <i>Genetics in Medicine</i> , 2017, 19, 599-603.	2.4	67
21	Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. <i>Oncogene</i> , 2005, 24, 1150-1158.	5.9	59
22	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56
23	Breast tumors from CHEK2 1100delC- mutation carriers: genomic landscape and clinical implications. <i>Breast Cancer Research</i> , 2011, 13, R90.	5.0	55
24	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014, 23, 6096-6111.	2.9	53
25	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	3.3	51
26	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
27	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	2.5	49
28	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	2.5	47
29	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
30	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39
31	Patient survival and tumor characteristics associated with CHEK2:p.1157T → findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016, 18, 98.	5.0	39
32	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
33	Identification and characterization of novel associations in the <i>CASP8/ALS2CR12</i> region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
34	Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 934-945.	2.5	37
35	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012, 33, 1123-1132.	2.5	35
36	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014, 23, 1934-1946.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
38	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
39	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26
40	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 463-469.	2.5	24
41	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18.	5.0	20
42	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2692-2700.	5.1	19
43	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
44	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 623-642.	2.5	19
45	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
46	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1783-1791.	2.5	17
47	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	12.8	16
48	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15
49	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	5.0	14
50	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	2.8	14
51	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020, 12, 292.	3.7	11
52	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
53	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
54	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6

#	ARTICLE	IF	CITATIONS
55	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
56	Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. <i>The HUGO Journal</i> , 2009, 3, 31-40.	4.1	5
57	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	5.2	5
58	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. <i>Cancers</i> , 2021, 13, 2907.	3.7	3
59	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 14763.	3.3	3
60	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
61	Abstract 758: The clinical utility of BRCA1/2 pathogenic variants in breast cancer patient prognosis. , 2021, , .		0